Search

Aim: It has recently been thought that obesity may cause metabolic diseases as well as being linked to immune system dysfunction. The purpose of this study was to compare tetanus antibody levels between patients with high body mass indices and healthy-weight individuals and to examine the effect of obesity on tetanus antibody levels in adults. Materials and Methods: This cross-sectional research was performed at Duzce University,Faculty of Medicine from December 2018 to February 2019. The study group was composed of obese patients who had undergone tetanus immunization within the previous 10 years. The control group consisted of healthy-weight individuals who had also been immunized in the previous 10 years. An enzyme-linked immunosorbent assay kit (Euroimmun, Germany) was used to detect antibodies to tetanus toxoid. Results: Sixty-seven individuals with obesity and 21 controls participated in this study. Anti-tetanus IgG antibodies were at protective levels in both groups, although the mean antibody level in the patients with obesity was significantly lower compared to the control group (0.788±0.602 vs 1.112±0.398, p=0.022). Anti-tetanus IgG antibodies were significantly negatively correlated with BMI (r=- 0.269, p=0.016). Conclusion: The detection of low levels of tetanus antibody titers in patients with high BMI in this study compared to the control group suggests that greater attention is required in this population. [ABSTRACT FROM AUTHOR]

Aim: Chronic hepatitis C virus (HCV) is considered a critical threat to the public health in the world. We compared treatment outcomes of Ombitasvir, Paritaprevir and Ritonavir with Dasabuvir (PrOD) and Ledipasvir (LDV) and Sofosbuvir (SOF) in real world patients with chronic HCV in treatment-naïve and pre-treated patients with chronic HCV. MaterialS and Methods: 91 adult patients enrolled in our study and were divided in two groups. The frst group; consisted of 53 patients, who orally received a fxed-dose combination tablet comprised of LDV and SOF once daily for 24 weeks. The second group; consisted of 38 patients, who orally received a fxed-dose combination tablet comprised of PrOD twice daily for 12 weeks without regard to fat or calorie content. Results: The results showed that sustained virologic response (SVR) rates were 100% in the both groups analyzed. 76 adverse events were occurred in total. 46 of overall adverse events were found on patients in the frst group and 30 of those events were found on patients in the second group. Weakness (13.1%), pruritus (5.5%), myalgia (1.1%) nausea (5.5%), dry mouth (1.1%) and insomnia (1.1%) were observed among the patients. Twelve weeks after initiating treatment, virologic suppression was accomplished for all patients in the both groups. Additionally, laboratory analysis concluded that HCV-RNA levels of the overall patients were negative after 48 weeks of the onset of the treatment. Conclusion: The real world comparative analysis of two distinct treatment regimens concluded that administration of PrOD and LDV/ SOF on the patients with chronic HCV has an extremely effective outcome. SVR12 rates of 100% were obtained in both treatment regimens for all treatment naïve and treatment-experienced patients regardless of cirrhosis occurrence and of HCV genotype. [ABSTRACT FROM AUTHOR]